Feds: Hedge Fund Benefited From Insider Trading     This is
MORNING EDITION from NPR News. I'm Renee Montagne.   And I'm
Linda Wertheimer.  Federal prosecutors in Manhattan have brought
charges in what they are calling the biggest insider trading
case ever. A former hedge fund employee made about a quarter
billion dollars for the fund after allegedly getting a sneak
preview of clinical trial data for a new drug.  NPR's Ailsa
Chang reports prosecutors believe this may lead them to even
bigger cases.  AILSA CHANG, BYLINE: Prosecutors say Mathew
Martoma first told his hedge fund SAC Capital to buy up the
stocks of two companies that were developing an Alzheimer's
drug. Then one day Martoma gets bad news. A doctor shows him
really disappointing clinical trial results. And that's when he
knew the fund needed to dump the stocks.  Here's Preet Bharara,
the U.S. attorney in Manhattan.  PREET BHARARA: Martoma went
from bull to bear, as he tried to dig his hedge fund out of a
massive hole.  CHANG: The hedge fund got ou